Antitumor agent effect enhancer containing IL-6 antagonist

• US 6,086,874 A
• Filed: 06/27/1997
• Issued: 07/11/2000
• Est. Priority Date: 12/29/1994
• Status: Expired due to Term

• Current Assignee: Chugai Seiyaku Kabushiki Kaisha (Roche Holding AG)
• Original Assignee: Chugai Seiyaku Kabushiki Kaisha (Roche Holding AG)
• Inventors: Yoshida, Osamu, Mizutani, Youichi
• Primary Examiner(s): Bansal, Geetha P.
• Application Number:
  US08/860,487
• Time in Patent Office: 1,110 Days
• Field of Search: 424/133.1, 424/143.1, 424/155.1, 424/141.1, 424/144.1, 424/145.1, 424/138.1, 424/152.1, 424/158.1, 424/172.1, 424/174.1, 530/387.1, 530/387.3, 530/387.7, 530/388.22
• US Class Current: 424/133.1
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/28 Compounds containing heavy metals
• CPC Class Codes: A61K 31/40 having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
• CPC Class Codes: A61K 31/555 containing heavy metals, e.g. hemin, hematin, melarsoprol
• CPC Class Codes: A61K 33/24 Heavy metals; Compounds thereof
• CPC Class Codes: A61K 33/243 Platinum; Compounds thereof
• CPC Class Codes: A61K 39/395 Antibodies agglutinins A61K38/36 ; as drug carriers A61K47/50; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

The present invention discloses an effect enhancer for antitumor agents, examples of which include platinum compounds such as cisplatin and carboplatin, and mitomycin C, that contains interleukin-6 (IL-6) antagonist, examples of which include antibody to IL-6, antibody to IL-6 receptor, and antibody to gp130 protein.

Claims

1. A kit comprising an antitumor agent, an interleukin-6 (IL-6) antagonist selected from the group consisting of anti-interleukin-6 (anti-IL-6) antibody and anti-interleukin-6 receptor (anti-IL-6R) antibody and a pharmaceutically acceptable carrier or diluent therefor, wherein said antitumor agent and interleukin-6 antagonist are not physically bonded.

2. A method of treating a tumor by inhibiting the development and growth of tumor cells, selected from the group consisting of tumors having an IL-6 receptor, tumors that grow by using IL-6 as a physiologically active substance, and tumors that exhibit resistance to therapy by IL-6 as a physiologically active substance in a subject, said method comprising administering to the subject an interleukin-6 (IL-6) antagonist selected from the group consisting of anti-interleukin-6 (anti-IL-6) antibody and anti-interleukin-6 receptor (anti-IL-6R) antibody in combination with an antitumor agent, wherein said antitumor agent and IL-6 antagonist are not physically bonded, to a patient in need of such treatment, wherein said IL-6 antagonist and antitumor agent are administered in an amount effective to treat said tumor.

3. A method of treating a tumor according to claim 2, wherein the tumor is selected from renal cell carcinoma, myeloma, ovarian cancer, B lymphoma of EB virus infection, adult T-cell leukemia, prostate cancer and Kaposi'"'"'s sarcoma.

4. A method of treating a tumor according to claim 2, wherein the IL-6 antagonist is a monoclonal antibody.

5. A method of treating a tumor according to claim 4, wherein said monoclonal antibody is PM-1 antibody.

6. A method of treating a tumor according to claim 5, wherein said PM-1 antibody is a humanized PM-1 antibody.

7. A method of treating a tumor according to claim 2, wherein the antitumor agent is a chemotherapeutic drug.

8. A method of treating a tumor according to claim 7, wherein the antitumor agent is selected from the group consisting of cisplatin, carboplatin, 254-S, DWA-2114R and NK-121.

9. A method of treating a tumor according to claim 7, wherein said chemotherapeutic drug is a platinum compound having an antitumor effect.

10. A method of treating a tumor according to claim 7, wherein said chemotherapeutic drug is mitomycin C.

11. A method of treating a tumor according to claim 2, wherein said IL-6 antagonist is human IL-6 antagonist.

12. A method of enhancing a therapeutic effect of an antitumor agent in a subject having a tumor selected from the group consisting of tumors having an IL-6 receptor, tumors that grow by using IL-6 as a physiologically active substance, and tumors that exhibit resistance to therapy by IL-6 as a physiologically active substance in a subject, said method comprising administering to the subject said antitumor agent in combination with an interleukin-6 (IL-6) antagonist selected from the group consisting of anti-interleukin-6 (anti-IL-6) antibody and anti-interleukin-6 receptor (anti-IL-6R) antibody, wherein said antitumor agent and IL-6 antagonist are not physically bonded, and wherein said IL-6 antagonist is administered in an amount effective to enhance the therapeutic effect of the antitumor agent.

13. A method of enhancing the therapeutic effect of an antitumor agent according to claim 12, wherein the IL-6 antagonist is a monoclonal antibody.

14. A method according to claim 13, wherein said monoclonal antibody is PM-1 antibody.

15. A method according to claim 14, wherein said PM-1 antibody is humanized PM-1 antibody.

16. A method of enhancing the therapeutic effect of an antitumor agent according to claim 12, wherein the antitumor agent is a chemotherapeutic drug.

17. A method according to claim 16, wherein said chemotherapeutic drug is a platinum compound having antitumor effects.

18. A method according to claim 16, wherein said chemotherapeutic drug is mitomycin C.

19. A method of enhancing the therapeutic effect of an antitumor agent according to claim 12, wherein the antitumor agent is selected from the group consisting of cisplatin, carboplatin, 254-S, DWA-2114R and NK-121.

20. A method according to claim 12, wherein said IL-6 antagonist is human IL-6 antagonist.